EPRX Eupraxia Pharmaceuticals Inc.
Company Analysis
Latest News
🟢 Eupraxia Pharmaceuticals is trading 12% up today in pre-market despite no clear overnight company-specific announcement
Eupraxia Pharmaceuticals is trading 12.43% up at $7.60 after no clear company-specific announcement was identified overnight. - Recent company news includes...
🔴 Eupraxia Pharmaceuticals is trading 7.28% down today in pre-market — no clear company-specific catalyst identified
Eupraxia Pharmaceuticals is trading 7.28% down at $6.50, with no clear company-specific negative announcement, filing, earnings update, or analyst action...
🟢 Eupraxia Pharmaceuticals is trading 8.21% up in pre-market — no clear catalyst identified
Eupraxia Pharmaceuticals is trading 8.21% up at $7.38 in pre-market, with no clear company-specific catalyst identified. - Compared with its August 17, 2026...
🔴 Eupraxia Pharmaceuticals is trading 11.58% down in pre-market as global risk sentiment weakens
Eupraxia Pharmaceuticals is trading 11.58% down at $6.03, coinciding with weaker global risk sentiment. - Shares closed at $6.82 on August 17, 2026. - No new...
🟢 Eupraxia Pharmaceuticals is trading 10.85% up in after-hours trading after durable symptom improvement in RESOLVE trial
Eupraxia Pharmaceuticals is trading now 10.85% up at $7.56 after new RESOLVE trial data showed durable symptom improvement in eosinophilic esophagitis. -...
Eupraxia's Once-a-Year Throat Treatment Posts Strong Year-Long Data — But Can a $475 Million Biotech Crack a Market Dominated by Sanofi?
Shares of Eupraxia Pharmaceuticals surged 8.6% to $7.30 after new data from the company's mid-stage clinical trial showed its experimental injection for a...
🟢 Eupraxia Pharmaceuticals is trading 8.63% up in pre-market after positive RESOLVE trial findings
Eupraxia Pharmaceuticals is trading 8.63% up now at $7.30 after positive RESOLVE trial findings for EP-104GI in eosinophilic esophagitis. - Painful and...
Eupraxia Pharmaceuticals reports sustained relief, eliminates severe swallowing pain
Eupraxia Pharmaceuticals Inc. announced positive results from a new analysis of its Phase 1b/2a RESOLVE trial for EP-104GI. The study targeted Eosinophilic...
🟢 Eupraxia Pharmaceuticals is trading 6% up today after Q2 earnings beat
Eupraxia Pharmaceuticals is trading 5.71% up now at $6.85 after its August 11, 2026 second-quarter earnings beat. - The results were supported by a $133.6...
🟢 Eupraxia Pharmaceuticals is trading 13% up in pre-market after Q2 report highlighted $133.7 million liquidity
Eupraxia Pharmaceuticals is trading sharply higher at $7.30, up +12.65%, after its August 11 Q2 report highlighted $133.7 million in liquidity and cash runway...
🟢 Eupraxia Pharmaceuticals is trading 8% up today in pre-market after Q2 EPS beat
Eupraxia Pharmaceuticals is trading $7.00 (+8.02%) in pre-market after reporting Q2 EPS of $(0.23), beating the $(0.25) estimate. - Management reported $133.7...
🟢 Eupraxia Pharmaceuticals is trading 5% up in after-hours trading after Q2 EPS beat estimates
Eupraxia Pharmaceuticals is trading $6.82 (+5.25%) after second-quarter 2026 EPS of $(0.23) beat the $(0.25) consensus estimate. • Reported a $14.5 million...
Eupraxia's Losses Nearly Double as It Bets Big on a Single Drug Trial — Can the Cash Last Long Enough to Prove It Works?
Shares of Eupraxia Pharmaceuticals plunged 11.9% to $5.90 on August 12 after second-quarter results revealed sharply escalating costs at this clinical-stage...
🔴 Eupraxia Pharmaceuticals is trading 11.9% down in pre-market after net loss widened to $14.5 million
Eupraxia Pharmaceuticals is trading 11.94% down at $5.90 after its August 11, 2026 second-quarter results showed a $14.5 million net loss, up from $8.7 million...
Eupraxia Pharmaceuticals' second quarter 2026 EPS beat estimates as liquidity reached $133.7M
Eupraxia Pharmaceuticals reported a net loss of $14.5 million for the second quarter of 2026, outperforming analyst expectations for the period. As a...
🔴 Eupraxia Pharmaceuticals is trading 5.17% down today in pre-market — No confirmed company-specific catalyst identified
Eupraxia Pharmaceuticals is trading 5.17% down at $6.42 in pre-market after declining from the August 7 close of $6.77; no confirmed company-specific...
🟢 Eupraxia Pharmaceuticals is trading 9.31% up in pre-market ahead of Q2 2026 earnings release
Eupraxia Pharmaceuticals is trading sharply higher at $7.40, up +9.31%, in pre-market on August 10, 2026, as investors may be positioning ahead of its Q2 2026...
Eupraxia Pharmaceuticals Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
For the second quarter of 2026, analysts expect Eupraxia Pharmaceuticals to report a consensus loss per share of $0.25 on zero revenue, with the current stock...
🔴 Eupraxia Pharmaceuticals is trading 11.4% down in pre-market with no confirmed catalyst identified
Eupraxia Pharmaceuticals is trading 11.4% down at $5.90 after no confirmed company-specific announcement, earnings release, or late-breaking catalyst was...
🟢 Eupraxia Pharmaceuticals is trading 12.6% up in after-hours trading — move remains unexplained
Eupraxia Pharmaceuticals is trading at $7.50 (+12.61%) in after-hours trading; the move remains unexplained. - No confirmed August 6, 2026 company-specific...